Novo Nordisk threatens legal action over Hims & Hers semaglutide pill
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
TD Cowen Reiterates Hold Rating on Hims and Hers (HIMS)
February 6, 2026 6:04 AM ESTTD Cowen analyst Jonna Kim reiterated a Hold rating and $30.00 price target on Hims and Hers (NYSE: HIMS).
The analyst comments "We are hosting a Pharmacy Law Expert Call: An Update On Oral And Injectable GLP-1 Compounding today (2/6) at 12:30pm ET - please contact your sales representative if you are interested.
HIMS announced that the launch of compounded semaglutide pills starting at $49 the first month with a 5 month-plan (remaining months at $99 per month). Our take is that without this announcement, compounded GLP-1 revenue would... More
